Literature DB >> 31996974

Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?

Nicolas Aide1,2,3, Michel De Pontdeville4, Egesta Lopci5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31996974     DOI： 10.1007/s00259-020-04702-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  18 in total

1.  18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns.

Authors:  O Humbert; N Cadour; M Paquet; R Schiappa; M Poudenx; D Chardin; D Borchiellini; D Benisvy; M J Ouvrier; C Zwarthoed; A Schiazza; M Ilie; H Ghalloussi; P M Koulibaly; J Darcourt; J Otto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-23       Impact factor: 9.236

2.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Authors:  Mario Sznol; Pier Francesco Ferrucci; David Hogg; Michael B Atkins; Pascal Wolter; Massimo Guidoboni; Celeste Lebbé; John M Kirkwood; Jacob Schachter; Gregory A Daniels; Jessica Hassel; Jonathan Cebon; Winald Gerritsen; Victoria Atkinson; Luc Thomas; John McCaffrey; Derek Power; Dana Walker; Rafia Bhore; Joel Jiang; F Stephen Hodi; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2017-09-15       Impact factor: 44.544

3.  Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.

Authors:  Hoda Anwar; Christos Sachpekidis; Julia Winkler; Annette Kopp-Schneider; Uwe Haberkorn; Jessica C Hassel; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-10       Impact factor: 9.236

4.  18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.

Authors:  Kimiteru Ito; Rebecca Teng; Heiko Schöder; John L Humm; Ai Ni; Laure Michaud; Reiko Nakajima; Rikiya Yamashita; Jedd D Wolchok; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2018-11-09       Impact factor: 10.057

Review 5.  18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond.

Authors:  Rodney J Hicks; Amir Iravani; Shahneen Sandhu
Journal:  PET Clin       Date:  2020-01

6.  Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.

Authors:  Romain-David Seban; John S Nemer; Aurélien Marabelle; Randy Yeh; Eric Deutsch; Samy Ammari; Antoine Moya-Plana; Fatima-Zohra Mokrane; Robyn D Gartrell; Grace Finkel; Luke Barker; Amélie E Bigorgne; Lawrence H Schwartz; Yvonne Saenger; Caroline Robert; Laurent Dercle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-25       Impact factor: 9.236

Review 7.  The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.

Authors:  Annie N M Wong; Grant A McArthur; Michael S Hofman; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-07       Impact factor: 9.236

8.  Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.

Authors:  Biagio Ricciuti; Carlo Genova; Maria Bassanelli; Andrea De Giglio; Marta Brambilla; Giulio Metro; Sara Baglivo; Maria Giovanna Dal Bello; Anna Ceribelli; Francesco Grossi; Rita Chiari
Journal:  Clin Lung Cancer       Date:  2019-02-27       Impact factor: 4.785

9.  Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

Authors:  P F Ferrucci; P A Ascierto; J Pigozzo; M Del Vecchio; M Maio; G C Antonini Cappellini; M Guidoboni; P Queirolo; P Savoia; M Mandalà; E Simeone; S Valpione; M Altomonte; F Spagnolo; E Cocorocchio; S Gandini; D Giannarelli; C Martinoli
Journal:  Ann Oncol       Date:  2016-01-22       Impact factor: 32.976

Review 10.  FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.

Authors:  Nicolas Aide; Rodney J Hicks; Christophe Le Tourneau; Stéphanie Lheureux; Stefano Fanti; Egesta Lopci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-05       Impact factor: 9.236
View more
  2 in total

1.  First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes.

Authors:  David Lang; Linda Ritzberger; Vanessa Rambousek; Andreas Horner; Romana Wass; Kaveh Akbari; Bernhard Kaiser; Jürgen Kronbichler; Bernd Lamprecht; Michael Gabriel
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

2.  Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer.

Authors:  Michael Beck; Sabine Semrau; Marlen Haderlein; Antoniu-Oreste Gostian; Julius Hartwich; Sarina Müller; Annett Kallies; Carol-Immanuel Geppert; Miriam Schonath; Florian Putz; Udo Gaipl; Benjamin Frey; Marc Saake; Heinrich Iro; Michael Uder; Arndt Hartmann; Torsten Kuwert; Rainer Fietkau; Markus Eckstein; Markus Hecht
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.